Form 4: Lineage Cell Therapeutics CFO Howe Granted 750,000 Stock Options

Lineage Cell Therapeutics' CFO, Jill Ann Howe, was granted 750,000 employee stock options on March 10, 2025, according to a Form 4 filing.

Summary

• Jill Ann Howe, the Chief Financial Officer of Lineage Cell Therapeutics, Inc., was granted 750,000 employee stock options.
• The options have an exercise price of $0.53.
• The grant date was March 10, 2025.
• One quarter of the options vest on March 10, 2026, and the remainder vest in 36 monthly installments thereafter, contingent upon continuous employment.
• The options expire on March 10, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued employment and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant and the vesting schedule are typical for a CFO at a company of Lineage Cell Therapeutics' size and stage of development.
• Comparable companies such as BioTime (now AgeX Therapeutics) and Asterias Biotherapeutics (acquired by BioTime) have used similar stock option grants to incentivize their executives.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates